Vical Files $70 Million Shelf Registration
Friday January 27, 7:30 am ET
SAN DIEGO, Jan. 27 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL - News) announced today that it has filed a shelf registration statement with the Securities and Exchange Commission (SEC), which upon being declared effective by the SEC, would allow Vical to issue from time to time an aggregate of up to $70 million of common stock, preferred stock or a combination of these securities. The shelf registration is intended to provide flexibility in financing the company's business needs. Specific terms of any offering under the shelf registration and the securities involved would be established at the time of sale.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company has retained all rights to its internally developed product candidates. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and serve significant unmet medical needs. Additional information on Vical is available at www.vical.com. |
